Divis Laboratories
Divis Laboratories, a leading player in the pharmaceutical and biotechnology sectors, is headquartered in Hyderabad, India. Founded in 1990, the company has established itself as a prominent manufacturer of active pharmaceutical ingredients (APIs) and intermediates, catering to a global clientele. With a strong focus on research and development, Divis Laboratories has achieved significant milestones, including the successful launch of several high-quality products that meet stringent regulatory standards. The company’s core offerings include APIs for various therapeutic areas, particularly in anti-retroviral and anti-cancer medications, which are distinguished by their purity and efficacy. Divis Laboratories is recognised for its robust market position, consistently ranking among the top suppliers in the industry. Its commitment to innovation and sustainability further enhances its reputation as a trusted partner in the pharmaceutical landscape.
DitchCarbon Score
How does Divis Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Divis Laboratories's score of 41 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Divis Laboratories's reported carbon emissions
In 2024, Divis Laboratories reported total greenhouse gas emissions of approximately 363,246,000 kg CO2e for Scope 1 and about 325,972,000 kg CO2e for Scope 2. This marks a reduction from 2023, where emissions were approximately 380,676,000 kg CO2e for Scope 1 and about 373,141,000 kg CO2e for Scope 2. The company has set ambitious targets to reduce its emissions intensity by 25% for both Scope 1 and Scope 2 by 2030, starting from a 2023 baseline. Divis Laboratories is committed to achieving net-zero greenhouse gas emissions across its entire value chain by 2050. The near-term targets include a significant reduction of 58.8% in absolute Scope 1 and 2 emissions by 2034, alongside a 35% reduction in absolute Scope 3 emissions within the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and are designed to keep global warming below 1.5°C. The company has demonstrated a proactive approach to climate commitments, with a clear roadmap for emissions reduction and a focus on sustainability within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 20,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Divis Laboratories is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
